Lipids behavior and adverse effects for oral antidiabetic agents in patients with Type 2 diabetes treated with sulfonylureas alone based on systematic review.
The secondary and adverse effects when biguanides, alpha-glycosidase inhibitor or thiazolidine derivative was used with sulphonylurea agent (SU) as compared with those with SU alone in Type 2 diabetes patients by using Systematic Review. Two-agent concurrent treatment groups, taken from studies in which subjects were assigned to a group given only a sulfonylurea agent and a group given a sulfonylurea agent with the other glycemic control agent (combination of a sulfonylurea agent and a biguanide agent (I), combination of a sulfonylurea agent and an alpha-glucosidase inhibitor (II), and combination of a sulfonylurea agent and thiazolidinedione (III)), were studied in a randomized controlled trial. The secondary efficacy outcome measures were total cholesterol (TC), triglyceride (TG), HDL-C, LDL-C, and change in body weight. The incidence of hypoglycemia, feeling of fullness, diarrhea, liver dysfunction, and edema was investigated as a safety outcome measure, and the clinical significance of concurrent treatment with a sulfonylurea agent in addition to the other glycemic control agent was investigated. With respect to (II), an antidiabetic effect was showed. As for (III), it had the disadvantage of increased body weight. Furthermore, increase of HDL-C levels, in particular, was observed. The improving effect of (III) on serum lipids may be clinically effective for considering the pathologic condition of diabetes, which is often complicated by hyperlipidemia.
Mukai
Junichi
J
Department of Pharmacy, Akita University Hospital, 1-1-1 Hondo Akita, Akita 010-8543, Japan.
Tada
Hitoshi
H
Watanabe
Yuka
Y
Miura
Masatomo
M
Katsuyama
Sou
S
Shoji
Tohru
T
Mohri
Kiminori
K
Mouri
Kiminori
K
Eto
Masaaki
M
Suzuki
Toshio
T
D000284:Administration, Oral; D001645:Biguanides / Q000008:administration & dosage* / Q000009:adverse effects*; D001835:Body Weight; D003924:Diabetes Mellitus, Type 2 / Q000097:blood* / Q000188:drug therapy* / Q000503:physiopathology; D004359:Drug Therapy, Combination; D004791:Enzyme Inhibitors / Q000008:administration & dosage* / Q000009:adverse effects*; D006442:Glycated Hemoglobin / Q000032:analysis; D006026:Glycoside Hydrolases / Q000037:antagonists & inhibitors*; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage* / Q000009:adverse effects*; D008055:Lipids / Q000097:blood*; D016032:Randomized Controlled Trials as Topic; D013453:Sulfonylurea Compounds / Q000008:administration & dosage* / Q000009:adverse effects*; D053778:Thiazolidines / Q000008:administration & dosage* / Q000009:adverse effects*
D001645:Biguanides; D004791:Enzyme Inhibitors; D006442:Glycated Hemoglobin; D006026:Glycoside Hydrolases; D007004:Hypoglycemic Agents; D008055:Lipids; D013453:Sulfonylurea Compounds; D053778:Thiazolidines; C517652:hemoglobin A1c protein, human